CLC Policy Issues: Other


	Home \| Sitemap \| Contact Info

	Clinical Trials—Medicare \| Clinical Trials—Private Insurance \| Medicare Payment FDA \| Cancer Research \| Stem Cell Research \| Privacy \| Other


		CLC Identifies Desirable Qualities for NCI Director (July 17, 2009) July 17, 2009 The President The White House Washington, D.C. 20500 Dear Mr. President: The undersigned organizations dedicated to cancer research, diagnosis and care applaud your commitment to the cancer research enterprise in the form of enhanced funding for the National Cancer Institute (NCI). In order to take optimal advantage of this important investment by the American people and to ensure that such funds are appropriately managed, the appointment of the Director of the NCI is critical. In anticipation of the appointment of a new NCI Director, our groups have developed a joint recommendation for qualities necessary in any candidate for this position. After extensive consultation, we have determined that the new NCI Director should be an individual who: Enjoys an outstanding research record and the respect of peers in cancer research; Possesses an understanding of translational and clinical research and an appreciation of the need for a balanced portfolio of basic and applied research; Is willing to maintain a high level of transparency and accountability regarding the NCI research program by engaging patient advocates and others outside the NCI organization in priority setting and portfolio review; Recognizes the necessity of research collaboration with extramural research organizations, including private research foundations and the pharmaceutical and biotechnology industries; Possesses management experience adaptable to budgetary environments of either restraint or growth and capable of creating a climate of collaboration among senior managers of the Institute; and Embraces an integrated and comprehensive approach to cancer care and research, encouraging research across the continuum of care. We strongly urge you to consider these qualities of consultation and collaboration in making your choice of a new NCI Director and look forward to working with you and your Administration for the benefit of people with, or at risk for, cancer. Sincerely, Cancer Leadership Council American Psychosocial Oncology Society American Society for Radiation Oncology Bladder Cancer Advocacy Network Breast Cancer Network of Strength Cancer Care The Children's Cause for Cancer Advocacy Coalition of Cancer Cooperative Groups International Myeloma Foundation Kidney Cancer Association Lance Armstrong Foundation The Leukemia & Lymphoma Society Lymphoma Research Foundation Multiple Myeloma Research Foundation National Coalition for Cancer Survivorship North American Brain Tumor Coalition Ovarian Cancer National Alliance Prevent Cancer Foundation Sarcoma Foundation of America Susan G. Komen for the Cure Advocacy Alliance Us TOO International Prostate Cancer Education and Support Network The Wellness Community cc: The Honorable Kathleen Sebelius Back to Other Index About CLC \| What's New \| Policy Issues \| Participants' Login Home \| Sitemap \| Contact Info Copyright © 2001-2002 Cancer Leadership Council. All rights reserved. Please send comments and suggestions to webmaster@cancerleadership.org.